Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of SH-1028 in Advanced Solid Cancer
NCT03618043Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Sep 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilertinib in malignant solid tumor and non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Maximum tolerated dose at 28 days and Incidence of Dose Limiting Toxicity at 28 days. Status: unknown.
02
Drugs
rilertinib
03
Conditions
malignant solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03618043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03618043.